Rigel Pharmaceuticals Inc (RIGL): who owns it and who trades it
As of Nov 16, 2026, RIGL insiders reported 3 open-market sales worth $306K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Kamil Ali-Jackson (Director), with $160K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Rigel Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns RIGL
155 funds and institutions reported RIGL shares worth $647M at the end of Q2 2026, about 89% of the company. The largest holder is BlackRock, Inc. with 10.5%.
Funds and institutions (13F) 89%Everyone else 11%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 1.94M | 10.48% | $75.9M | +10% |
| Soleus Capital Management, L.P. | 1.84M | 9.96% | $72.1M | – |
| Armistice Capital, LLC | 1.67M | 9.04% | $65.4M | +31% |
| State Street Corp | 1.04M | 5.62% | $40.7M | -7% |
| Vanguard Capital Management LLC | 785,107 | 4.24% | $30.7M | +3% |
| American Century Companies Inc | 741,718 | 4.01% | $29M | +36% |
| Lsv Asset Management | 721,666 | 3.90% | $28.2M | +20% |
| Acadian Asset Management LLC | 591,686 | 3.20% | $23.1M | -11% |
| D. E. Shaw & Co., Inc. | 542,539 | 2.93% | $21.2M | +22% |
| Geode Capital Management, LLC | 483,175 | 2.61% | $18.9M | +10% |
| Marshall Wace, LLP | 367,393 | 1.99% | $14.4M | -39% |
| CM Management, LLC | 250,000 | 1.35% | $9.8M | +6% |
| Vanguard Portfolio Management LLC | 233,728 | 1.26% | $9.1M | +58% |
| Dimensional Fund Advisors LP | 227,951 | 1.23% | $8.9M | -40% |
| Goldman Sachs Group Inc | 226,780 | 1.23% | $8.9M | -48% |
| Two Sigma Investments, LP | 207,578 | 1.12% | $8.1M | -49% |
| Nomura Asset Management International Inc. | 195,000 | 1.05% | $7.6M | – |
| Morgan Stanley | 186,049 | 1.01% | $7.3M | +88% |
| Charles Schwab Investment Management Inc | 154,627 | 0.84% | $6M | -13% |
| Sixth Street Partners Management Company, L.P. | 154,627 | 0.84% | $6M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, RIGL insiders reported $0 of open-market purchases and $306K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Kamil Ali-Jackson | Director | Sale | 2,500 | $35.00 | $87.5K | Form 4 |
| May 26, 2026 | Kamil Ali-Jackson | Director | Sale | 2,500 | $29.17 | $72.9K | Form 4 |
| Feb 20, 2026 | Walter H Moos | Director | Sale | 4,000 | $36.36 | $145K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Kamil Ali-Jackson | Director | – | $160K | Jun 22, 2026 |
| Walter H Moos | Director | – | $145K | Feb 20, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
RIGL short interest
High short interest. 13.6% of RIGL shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 36%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.54M RIGL shares were sold short, 13.6% of the shares outstanding, down 7.2% from the report before. At the average daily volume of 196,113 shares, buying them all back would take about 12.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.54M | 13.57% | -7% | 196,113 | 12.9 |
| Oct 15, 2026 | 2.73M | 14.63% | -4% | 213,492 | 12.8 |
| Sep 30, 2026 | 2.86M | 15.29% | -11% | 256,338 | 11.1 |
| Sep 15, 2026 | 3.19M | 17.09% | +0% | 201,576 | 15.8 |
| Aug 31, 2026 | 3.18M | 17.03% | -1% | 349,183 | 9.1 |
| Aug 14, 2026 | 3.20M | 17.15% | +4% | 328,254 | 9.8 |
| Jul 31, 2026 | 3.09M | 16.56% | -2% | 293,137 | 10.6 |
| Jul 15, 2026 | 3.16M | 17.07% | -3% | 401,367 | 7.9 |
| Jun 30, 2026 | 3.25M | 17.58% | -6% | 452,745 | 7.2 |
| Jun 15, 2026 | 3.46M | 18.69% | -12% | 309,283 | 11.2 |
| May 29, 2026 | 3.93M | 21.27% | -0% | 327,363 | 12.0 |
| May 15, 2026 | 3.95M | 21.33% | +0% | 526,989 | 7.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Rigel Pharmaceuticals company events
Rigel Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jul 1, 2026LeadershipRigel Pharmaceuticals, Inc. announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company. Filing
- Jun 17, 2026DealAs previously disclosed in the Current Report on Form 8-K filed by Rigel Pharmaceuticals, Inc. on May 12, 2026, the Company entered into a License Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc., pursuant to which the Licensors granted the… Filing
- May 20, 2026LeadershipAt the 2026 Annual Meeting of Stockholders of Rigel Pharmaceuticals, Inc., the Company’s stockholders approved an amendment to the Company’s 2018 Equity Incentive Plan, as amended, to, among other things, add an additional 500,000 shares to the number of shares of common stock authorized for… Filing
- May 12, 2026AgreementRigel Pharmaceuticals, Inc. entered into a License Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 21, 2026AgreementEnded an important agreement. Filing
- Mar 3, 2026ResultsReleased financial results. Filing
- Feb 3, 2026LeadershipMichael P. Miller was appointed to serve on the board of directors of Rigel Pharmaceuticals, Inc., upon the recommendation of the Board’s Corporate Governance, Health Care Compliance Oversight and Nominating Committee, until his successor is elected and has qualified, or sooner in the event of his… Filing
- Jan 12, 2026AnnouncementBelow, on January 12, 2026, Rigel Pharmaceuticals, Inc. provided, on a preliminary and unaudited basis, certain estimated financial results for its fourth quarter and fiscal year ended December 31, 2025. Filing
- Dec 10, 2025AnnouncementRigel Pharmaceuticals, Inc. announced certain data from its ongoing Phase 1b study evaluating R289 in lower-risk myelodysplastic syndrome. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Rigel Pharmaceuticals financials
Famous investors that hold RIGL
3 of the 50 well-known investors we track reported holding RIGL in their latest 13F filing. The largest position is Jim Simons's, worth $3.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 73,119 | $3.5M | 0.0% | -50% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 13,651 | $657K | 0.0% | New |
| Israel Englander · Millennium Management | Q3 2026 | 11,750 | $566K | 0.0% | -87% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named RIGL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 8.2% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 8.2% |
| Nov 13, 2026 | Morgan Stanley | 13G | 6.5% |
| Nov 13, 2026 | Morgan Stanley | 13G | 6.5% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.7% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 4.7% |
Questions about Rigel Pharmaceuticals Inc (RIGL) stock
Who owns the most RIGL stock?
The largest reported owner of Rigel Pharmaceuticals Inc (RIGL) is BlackRock, Inc., with 10.5% of the company. In total, 155 funds and institutions reported holding RIGL at the end of Q2 2026, together about 89% of the shares. See the largest owners.
Are RIGL insiders buying or selling?
In the last 12 months, RIGL insiders reported no open-market purchases and 3 sales worth $306K. The latest trade was on Jun 22, 2026. See every trade.
What is the short interest in RIGL?
As of Oct 30, 2026, 2.54M RIGL shares were sold short, 13.6% of the shares outstanding, down 7.2% from the report before. At the average daily volume of 196,113 shares, buying them all back would take about 12.9 trading days (days to cover). See the history.
Which famous investors hold RIGL?
3 of the 50 well-known investors we track reported RIGL in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $3.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.